Register with MSD Connect
✔ Sign up for events
✔ Complete learning modules
✔ Receive cancer resources
✔ Access additional content
KEYNOTE-189 data presentation: KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 5.94 MB
Download our KEYNOTE-189 slide deck that discusses KEYTRUDA + plat-pem clinical data in metastatic non-squamous untreated NSCLC in adults whose tumours have no EGFR- or ALK-positive mutations.
Find out more information about KEYTRUDA in metastatic NSCLC:
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
